| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000335604 |
| P698 | PubMed publication ID | 22343254 |
| P2093 | author name string | John Edelsberg | |
| Gary Lyman | |||
| Derek Weycker | |||
| Rich Barron | |||
| Alex Kartashov | |||
| P2860 | cites work | Bending the Cost Curve in Cancer Care | Q22248106 |
| Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data | Q31151207 | ||
| Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities | Q33354335 | ||
| 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study | Q33768732 | ||
| Triple-negative breast cancer: role of specific chemotherapy agents | Q33900930 | ||
| 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline | Q34523108 | ||
| Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients | Q34566114 | ||
| Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status | Q34581334 | ||
| Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. | Q36611011 | ||
| International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy | Q37329165 | ||
| Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy | Q40412998 | ||
| Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia | Q40428333 | ||
| Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy | Q40510334 | ||
| Study of low-dose capecitabine monotherapy for metastatic breast cancer | Q43091436 | ||
| Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer | Q44067888 | ||
| Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia | Q44230472 | ||
| A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy | Q44253334 | ||
| Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. | Q44362096 | ||
| Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices | Q44691615 | ||
| Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer. | Q46038642 | ||
| Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy | Q46399690 | ||
| Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. | Q51819229 | ||
| P433 | issue | 1 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 8-18 | |
| P577 | publication date | 2012-02-14 | |
| P1433 | published in | Chemotherapy | Q2440355 |
| P1476 | title | Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer | |
| P478 | volume | 58 |
| Q57109294 | Accuracy of administrative databases in detecting primary breast cancer diagnoses: a systematic review |
| Q39095898 | Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic |
| Q46388405 | Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy |
| Q38823135 | Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012. |
| Q37710149 | Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma |
| Q51746755 | Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer. |
| Q88946019 | Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution |
| Q43571500 | Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database |
| Q41139035 | Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population |
| Q40242261 | Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings |
| Q34127931 | Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting |
| Q38068457 | Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia. |
| Q39698919 | Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies |
| Q51282624 | Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer. |
| Q47668200 | Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. |
| Q36723903 | Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter? |
| Q36840636 | Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice |
| Q45182863 | Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens |
| Q40320980 | Risk of infection among patients with non-metastatic solid tumors or non-Hodgkin's lymphoma receiving myelosuppressive chemotherapy and antimicrobial prophylaxis in US clinical practice |
| Q36502027 | Tamoxifen induces hepatotoxicity and changes to hepatocyte morphology at the early stage of endocrinotherapy in mice |
| Q39272804 | The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells |
| Q47969501 | Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer |
| Q36762853 | Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy |
| Q35963416 | Validity of breast, lung and colorectal cancer diagnoses in administrative databases: a systematic review protocol |
Search more.